Synthetic biology company Zymergen saw its shares plummet nearly 70% on Tuesday after the company said that product revenue would be “immaterial” in 2022 and that its Chief Executive was stepping down. The company, which went public at $31 a share in April, traded as high as $48.50, valuing the company at $4.8 billion. On … Continue reading “Zymergen Shares Sink After Company Loses CEO and Says This”
